Clene to File Accelerated Approval NDA for ALS Drug CNM-Au8 Following Positive FDA Meeting
CLNN has more than doubled off its 52-week low of $2.28.
Summary
Clene Inc. announced positive feedback from the FDA, indicating its data may support an accelerated approval New Drug Application (NDA) for its ALS drug candidate, CNM-Au8, which the company plans to submit in Q3 2026.
Key Events · Product Development and Regulatory · CLNN
-
FDA Greenlights Accelerated Approval Pathway
The FDA stated that Clene's proposed data may be capable of supporting an accelerated approval New Drug Application (NDA) for CNM-Au8 for the treatment of ALS.
-
NfL Acknowledged as Potential Surrogate Endpoint
The FDA noted that Neurofilament light (NfL) could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval for CNM-Au8.
-
NDA Submission Planned for Q3 2026
Clene Inc. intends to submit its New Drug Application (NDA) for CNM-Au8 to the FDA in the third quarter of 2026.
-
Phase 3 Confirmatory Study to Commence in Q1 2027
The company is conducting a Phase 3 confirmatory study for CNM-Au8, which it intends to commence in the first quarter of 2027.
Analysis · CLNN · Life Sciences
This announcement is a critical positive development for Clene Inc., especially given the company's recent disclosure of substantial doubt about its ability to continue as a going concern. The FDA's indication that Clene's data may support an accelerated approval pathway for its ALS drug candidate, CNM-Au8, and the acknowledgment of Neurofilament light (NfL) as a potential surrogate endpoint, significantly de-risks the regulatory path. An accelerated approval could bring the drug to market much faster, providing a potential revenue stream that is vital for the company's long-term viability. Investors should closely monitor the planned NDA submission in Q3 2026 and the subsequent FDA review process, as this represents a major step towards commercialization and could fundamentally alter the company's financial outlook.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $6.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.3M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.